B. Braun obtains permanent injunction

Published: 5-May-2011
Regulatory

Prevails in case against Terumo Corporation for its Introcan Safety IV catheter patent


German medical device manufacturer B. Braun Melsungen AG and its US subsidiary B. Braun Medical Inc. have succeeded in obtaining a permanent injunction in the patent infringement case against Japan's Terumo Corporation and its US subsidiary Terumo Medical Corporation.

On 21 April 2011, the US District Court for the District of Delaware granted an immediate and permanent order stopping Terumo from selling, or offering to sell, the Surshield Safety IV catheter in the acute care market, precluding Terumo from bidding against B. Braun on expiring GPO contracts.

Terumo will be permitted to continue selling the Surshield Safety IV catheter into the alternative care market until 1 June 2012, after which it cannot make, sell, use or offer the Surshield Safety Catheter in the US. B. Braun will seek damages and other relief for Terumo's infringement.

B. Braun's win follows a previous verdict awarded in November 2010, confirming the validity of an infringed claim of B. Braun's 2007 patent (US Patent 7,264,613) for its Introcan Safety IV Catheter.

  • Companies:
  • B Braun Aseptic Consulting Service
See more

You may also like

Regulatory

B. Braun introduces WHIN Safe Huber Needle

Read more
Helps protect against needle-stick injuries, blood and fluid exposure

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

B. Braun introduces WHIN Safe Huber Needle

Helps protect against needle-stick injuries, blood and fluid exposure
Regulatory

Accelerating and enhancing toxicology assessments

Infographic guides users through ToxHQ’s speedy assessment features
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535

Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain

With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
Regulatory

Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license

The licensing deal with Chiome enhances its open innovation platform
Manufacturing

Solvent recycler SPR-200 boosts sustainability in pharma labs

Recycling up to 90% of solvent in isocratic HPLC improves lab efficiency and sustainability
Subscribe now